RxDoctor Payments Data

Troy Boovy, NP

Psychiatric/Mental Health · Salisbury, NCNPI 1215055637

Payments from drug & device makers

$4,766in general payments, 2019–2025

Across 228 payments — averaging $20.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$826
  • Otsuka America Pharmaceutical, Inc.$748
  • Neurocrine Biosciences, Inc.$655
  • Teva Pharmaceuticals USA, Inc.$628
  • E.r. Squibb & Sons, L.L.C.$462
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$388
  • plus $1K from 9 others

What the payments were for

  • Food & beverage$4,48994%
  • Education$2776%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,766 in reported general payments places this provider in the 90th percentile of 947 psychiatric/mental health providers in North Carolina.

See all psychiatric/mental health providers in North Carolina

Medicare billing

Part B allowed, 2024
$18,381
Medicare patients
61
Services billed
192

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega TrinzaPaliperidone Palmitate43$328,878
IngrezzaValbenazine Tosylate23$184,402
Invega SustennaPaliperidone Palmitate74$182,106
Abilify MaintenaAripiprazole50$154,304
AristadaAripiprazole Lauroxil24$71,078
RexultiBrexpiprazole23$37,298
Risperdal ConstaRisperidone Microspheres12$27,735
VivitrolNaltrexone Microspheres11$18,508
Clozapine94$6,485
Paliperidone ErPaliperidone27$3,879
Buspirone Hcl255$3,702
Divalproex Sodium108$3,301
Quetiapine Fumarate142$2,947
Aripiprazole129$2,916
Bupropion XlBupropion Hcl161$2,684

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Trinza, Invega Sustenna, Risperdal Consta$338$538,719129 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$748$191,60173 claims
Neurocrine Biosciences, Inc.Ingrezza$655$184,40223 claims
Alkermes, Inc.Aristada, Vivitrol$826$89,58635 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 947 psychiatric/mental health providers in North Carolina.

Other psychiatric/mental health in Salisbury

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →